Mobility/Inflammation/Beauty

Palmitoylethanolamide (PEA)

Fatty acid amide that modulates mast cells and receptors to reduce chronic neuropathic pain and skin inflammation.

Palmitoylethanolamide (PEA)

Fatty acid amide that modulates mast cells and receptors to reduce chronic neuropathic pain and skin inflammation.

score

evidence

Safe

risk

Proven Benefits

01Reduces chronic neuropathic pain

02May lower inflammatory markers

03May improve atopic dermatitis sympt

Chemical Forms

Recommended

Micronized PEA (um-PEA)
Ultra-micronized PEA (um-PEA)

Avoid

Non-micronized PEA (poorer dissolution and absorption)

Expert Note

Micronization reduces particle size to roughly 1-10 μm, dramatically increasing surface area and intestinal absorption compared with standard PEA. Most positive clinical trials for pain and skin conditions used ultra-micronized forms, while non-micronized preparations have lower and more variable bioavailability.

Protocol

Amount

600 mg

Frequency

Twice daily for 3-4 weeks, then once daily

When

With or after meals to minimize mild stomach discomfort; consistency matters more than specific timing.

Condition-Based Dosing

Acute sciatica or severe neuropathic pain

600 mg twice daily for 3-6 weeks, then taper to 600 mg once daily— Taper based on symptom relief; many studies use this induction-maintenance model.

Maintenance or mild chronic pain

300-600 mg once daily— Lower doses may suffice for long-term maintenance after initial response.

Atopic dermatitis (adjunctive)

300 mg twice daily for 8-12 weeks— Used alongside standard topical therapy; evidence is preliminary.

Safety & Limits

Upper Safe Limit

1200 mg/day (highest daily dose studied in RCTs without serious adverse effects)

Cycling

Safe for continuous use

Contraindications

Pregnancy or breastfeeding — insufficient safety data; avoid unless supervised.

Known soy or peanut allergy — verify non-allergenic source material.

Updated Invalid Date